Breaking News Instant updates and real-time market news.

PTLA

Portola Pharmaceuticals

$37.77

0.14 (0.37%)

, CELG

Celgene

$91.23

0.92 (1.02%)

08:04
08/09/18
08/09
08:04
08/09/18
08:04

Portola Pharmaceuticals names Ernie Meyer as CHRO

Portola Pharmaceuticals (PTLA) announced the appointment of Ernie Meyer as executive vice president and chief human resources officer, effective August 20. As a member of the Executive Committee, Mr. Meyer will report to John T. Curnutte, M.D., Ph.D., interim co-president of Portola and head of research and development, with responsibility for leading the development and execution of the Company's global human resources strategy. Meyer joins Portola from Celgene (CELG), where he spent more than 13 years in positions of increasing scope and responsibility. Most recently, Mr. Meyer served as executive vice president of human resources & corporate services.

PTLA

Portola Pharmaceuticals

$37.77

0.14 (0.37%)

CELG

Celgene

$91.23

0.92 (1.02%)

  • 09

    Aug

  • 25

    Aug

  • 29

    Oct

PTLA Portola Pharmaceuticals
$37.77

0.14 (0.37%)

05/07/18
SBSH
05/07/18
NO CHANGE
Target $64
SBSH
Buy
Portola Pharmaceuticals price target raised to $64 from $58 at Citi
Citi analyst Yigal Nochomovitz raised his price target for Portola Pharmaceuticals to $64 following the FDA approval of Andexxa. The analyst keeps a Buy rating on the shares.
05/07/18
OPCO
05/07/18
NO CHANGE
Target $80
OPCO
Outperform
Portola Pharmaceuticals price target raised to $80 from $67 at Oppenheimer
Oppenheimer analyst Jay Olson raised his price target for Portola Pharmaceuticals to $80 from $67 after AndexXa received FDA approval as the first and only antidote indicated for patients treated with rivaroxaban and apixaban when reversal is needed in the case of life-threatening or uncontrolled bleeding. The analyst believes potential drivers of upside include AndexXa likely expanding factor Xa use and label extensions, U.S. approval of Gen2 manufacturing to expand capacity, European CHMP opinion in Q4 and cerdulatinib data at ASCO. Olson reiterates an Outperform rating on the shares.
05/07/18
MSCO
05/07/18
NO CHANGE
Target $46
MSCO
Equal Weight
Portola price target raised to $46 from $31 at Morgan Stanley
Morgan Stanley analyst Matthew Harrison raised his price target on Portola Pharmaceuticals to $46 following the FDA approval of AndexXa, calling it a significant positive. However, he maintains an Equal Weight rating on the shares, as he expects the stock to trade with the market given the limited launch will not allow investors to gauge true demand until 2019.
06/14/18
SBSH
06/14/18
NO CHANGE
SBSH
Buy
Portola not planning sale despite CEO transition, says Citi
Citi analyst Yigal Nochomovitz asked Portola Pharmaceuticals if the CEO transition means the company is potentially up for sale. Management emphasized that the CEO transition should not be interpreted as meaning they are planning to sell the company, Nochomovitz tells investors in a research note. He points out that management reiterated they are working towards advancing the company commercially. With two approved drugs in thrombosis, Portola views itself as well positioned to attract new talent to continue to build its sales force, Nochomovitz writes after speaking to the company. He keeps a Buy rating on the shares.
CELG Celgene
$91.23

0.92 (1.02%)

07/24/18
JPMS
07/24/18
NO CHANGE
JPMS
Overweight
Celgene positive headline streak continues, says JPMorgan
Last night's positive topline data for Revlimid plus Rituxan in relapsed/refractory indolent lymphoma is a "clear win" at a time when Celgene "really needed a string of favorable events," JPMorgan analyst Cory Kasimov tells investors in a research note titled "Positive Headline Streak Continues with AUGMENT." The analyst sees this indication as a "meaningful" near-term sales opportunity for the franchise prior to loss of exclusivity, potentially $600M in the U.S. alone. He expects the positive data to "modestly bolster sentiment" into Celgene's Q2 results. Kasimov keeps an Overweight rating on the shares.
07/26/18
PIPR
07/26/18
NO CHANGE
Target $95
PIPR
Neutral
Longer term concerns remain despite 'impressive' Q2 for Celgene, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond reiterates a Neutral rating and $95 price target for Celgene despite a "solid" Q2 results. With an "impressive" $110M Revlimid beat this quarter and $200M guidance increase, Celgene continues its pattern of strong Q2 performance, he notes. But despite this commercial execution, Raymond's concerns with respect to the company's ability to diversify away from Revlimid remain and he continues to prefer the sidelines on this name.
07/30/18
RHCO
07/30/18
NO CHANGE
Target $101
RHCO
Hold
Celgene price target raised to $101 from $96 at SunTrust
SunTrust analyst Yatin Suneja raised his price target on Celgene to $101 after its Q2 results, saying the company saw "good performances from all core products except Otezla and Abraxan", while its updated FY18 outlook also reflects its larger than anticipated share buyback. Suneja further notes that Celgene's pipeline assets ozanimod, fedratinib, luspatercept and the CAR-T programs are all progressing towards filings, which may help the company diversify its pipeline away from Revlimid. The analyst also keeps his Hold rating, noting that any near-term contribution from its extensive pipeline are likely to be limited.
08/08/18
RBCM
08/08/18
NO CHANGE
Target $110
RBCM
Outperform
RBC Capital revisits idea of Celgene going private after Tesla proposal
Following yesterday's news that Tesla (TSLA) CEO Elon Musk would like to see his company go private, RBC analyst Brian Abrahams revisited his prior analysis of whether Celgene (CELG) should go private in order to better capture the medium-term value of future Revlimid cash flows not being appreciated by public markets and avoid volatility as it transitions to a post-Revlimid business model. Though acknowledging that the two companies are in completely different industries, he thinks the example of Musk shows that performing such a transaction on a large company "may not be completely unrealistic," Abrahams said. Such an LBO, or perhaps more likely an acquisition by a larger pharmaceutical company, could possibly help capture more value from Celgene's commercial and pipeline products, concludes Abrahams, who has an Outperform rating and $110 price target on Celgene shares.

TODAY'S FREE FLY STORIES

03:25
09/25/18
09/25
03:25
09/25/18
03:25
General news
FX Action: USD-CAD has settled in the mid 1.2900s »

FX Action: USD-CAD has…

03:05
09/25/18
09/25
03:05
09/25/18
03:05
General news
FX Update: Most pairings and cross rates have posted narrow ranges »

FX Update: Most pairings…

ASPS

Altisource

$34.41

0.31 (0.91%)

02:55
09/25/18
09/25
02:55
09/25/18
02:55
Conference/Events
Altisource to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

02:10
09/25/18
09/25
02:10
09/25/18
02:10
General news
FX Action: USD-JPY posted a two-month high »

FX Action: USD-JPY posted…

01:35
09/25/18
09/25
01:35
09/25/18
01:35
General news
Asian Market Wrap: »

Asian Market Wrap:…

FDS

FactSet

$231.53

-0.05 (-0.02%)

, JBL

Jabil

$30.08

0.22 (0.74%)

20:25
09/24/18
09/24
20:25
09/24/18
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

FDS

FactSet

$231.53

-0.05 (-0.02%)

JBL

Jabil

$30.08

0.22 (0.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 25

    Sep

  • 27

    Sep

  • 01

    Oct

  • 09

    Oct

  • 13

    Nov

LOXO

Loxo Oncology

$163.07

3.91 (2.46%)

20:16
09/24/18
09/24
20:16
09/24/18
20:16
Hot Stocks
Loxo Oncology granted orphan status for solid tumors treatment »

The FDA granted Loxo…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 27

    Nov

PTLA

Portola Pharmaceuticals

$27.16

-0.39 (-1.42%)

20:15
09/24/18
09/24
20:15
09/24/18
20:15
Hot Stocks
Portola granted orphan status for cerdulatinib »

The FDA granted Portola…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Dec

TNC

Tennant

$72.75

-1.15 (-1.56%)

20:01
09/24/18
09/24
20:01
09/24/18
20:01
Hot Stocks
Tennant to Acquire Gaomei Cleaning Equipment Company, terms not stated »

Tennant Company announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VNO

Vornado

$73.52

-1.58 (-2.10%)

19:20
09/24/18
09/24
19:20
09/24/18
19:20
Hot Stocks
Vornado now owns 100% interest in retail condo at Marriott Marquis Times Square »

Vornado Realty Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

GOOG

Alphabet

$1,173.38

7.17 (0.61%)

, GOOGL

Alphabet Class A

$1,179.78

7.56 (0.64%)

19:08
09/24/18
09/24
19:08
09/24/18
19:08
Periodicals
Google CEO to meet with top Republican lawmakers Friday, WSJ says »

Google CEO Sundar Pichai…

GOOG

Alphabet

$1,173.38

7.17 (0.61%)

GOOGL

Alphabet Class A

$1,179.78

7.56 (0.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 21

    Oct

  • 25

    Oct

  • 25

    Oct

  • 28

    Oct

  • 07

    Nov

  • 03

    Mar

ASNA

Ascena Retail

$4.02

-0.21 (-4.96%)

, BAS

Basic Energy

$9.44

0.18 (1.94%)

18:56
09/24/18
09/24
18:56
09/24/18
18:56
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: Ascena…

ASNA

Ascena Retail

$4.02

-0.21 (-4.96%)

BAS

Basic Energy

$9.44

0.18 (1.94%)

KEG

Key Energy

$13.46

-0.18 (-1.32%)

PSTI

Pluristem

$1.31

(0.00%)

ARNA

Arena Pharmaceuticals

$42.80

-1.05 (-2.39%)

NOVN

Novan

$2.72

0.015 (0.56%)

SNDX

Syndax

$7.23

0.46 (6.79%)

DCPH

Deciphera

$39.80

0.78 (2.00%)

BJ

BJ's Wholesale

$28.47

-0.68 (-2.33%)

PETQ

PetIQ

$41.07

-0.55 (-1.32%)

CNP

CenterPoint Energy

$27.81

-0.23 (-0.82%)

CTL

CenturyLink

$22.90

-0.04 (-0.17%)

PBR

Petrobras

$11.40

-0.105 (-0.91%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 24

    Sep

  • 01

    Oct

  • 02

    Oct

  • 02

    Oct

  • 03

    Oct

  • 04

    Oct

  • 28

    Oct

  • 08

    Nov

  • 27

    Nov

  • 26

    Sep

  • 27

    Sep

  • 27

    Sep

PBR

Petrobras

$11.40

-0.105 (-0.91%)

18:54
09/24/18
09/24
18:54
09/24/18
18:54
Hot Stocks
Breaking Hot Stocks news story on Petrobras »

Petrobras reports August…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VRSN

VeriSign

$158.97

-0.79 (-0.49%)

18:39
09/24/18
09/24
18:39
09/24/18
18:39
Recommendations
VeriSign analyst commentary at JPMorgan »

VeriSign price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TI

Telecom Italia

$6.54

-0.1 (-1.51%)

18:35
09/24/18
09/24
18:35
09/24/18
18:35
Periodicals
Telecom Italia discussed Nextel bid at board meeting, Bloomberg says »

Telecom Italia's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INSG

Inseego

$4.01

-0.08 (-1.96%)

18:31
09/24/18
09/24
18:31
09/24/18
18:31
Hot Stocks
Inseego names John Weldon to head Enterprise SaaS Solutions division »

Inseego announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PCG

PG&E

$46.30

-0.48 (-1.03%)

18:31
09/24/18
09/24
18:31
09/24/18
18:31
Periodicals
PG&E says will invest $360M in electric car infrastructure, Bloomberg says »

PG&E senior manager…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 08

    Oct

  • 11

    Nov

KKR

KKR

$28.25

-0.01 (-0.04%)

18:21
09/24/18
09/24
18:21
09/24/18
18:21
Hot Stocks
KKR announces intra-quarter Q3 monetization activity »

KKR announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UNH

UnitedHealth

$267.35

0.6 (0.22%)

, EVHC

Envision Healthcare

$45.72

0.07 (0.15%)

18:17
09/24/18
09/24
18:17
09/24/18
18:17
Periodicals
UnitedHealth tells Hospitals about Envision ER contracts, Reuters says »

UnitedHealth (UNH) plans…

UNH

UnitedHealth

$267.35

0.6 (0.22%)

EVHC

Envision Healthcare

$45.72

0.07 (0.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 16

    Oct

AMZN

Amazon.com

$1,934.50

16.75 (0.87%)

, UBER

Uber

$0.00

(0.00%)

18:14
09/24/18
09/24
18:14
09/24/18
18:14
Periodicals
Amazon has made two approaches to buy Deliveroo, Telegraph reports »

Amazon has made two…

AMZN

Amazon.com

$1,934.50

16.75 (0.87%)

UBER

Uber

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

BK

BNY Mellon

$52.36

-0.9 (-1.69%)

17:48
09/24/18
09/24
17:48
09/24/18
17:48
Hot Stocks
BNY Mellon Investment Management to close EACM Advisors »

BNY Mellon Investment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

EPZM

Epizyme

$10.23

-0.075 (-0.73%)

17:44
09/24/18
09/24
17:44
09/24/18
17:44
Initiation
Epizyme initiated at Leerink »

Epizyme initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 02

    Oct

NAVB

Navidea

$0.25

-0.0135 (-5.14%)

17:31
09/24/18
09/24
17:31
09/24/18
17:31
Hot Stocks
Breaking Hot Stocks news story on Navidea »

John K. Scott, Jr.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LYL

Dragon Victory

$1.46

(0.00%)

17:30
09/24/18
09/24
17:30
09/24/18
17:30
Hot Stocks
Breaking Hot Stocks news story on Dragon Victory »

White Knight Ltd reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RDS.A

Royal Dutch Shell

$68.18

0.89 (1.32%)

, RDS.B

Royal Dutch Shell

$70.25

0.67 (0.96%)

17:30
09/24/18
09/24
17:30
09/24/18
17:30
Periodicals
Shell CEO weighs $30B LNG export terminal in Canada, WSJ says »

Royal Dutch Shell CEO Ben…

RDS.A

Royal Dutch Shell

$68.18

0.89 (1.32%)

RDS.B

Royal Dutch Shell

$70.25

0.67 (0.96%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.